Online citations, reference lists, and bibliographies.
← Back to Search

Investigation Of Properties And Recrystallisation Behaviour Of Amorphous Indomethacin Samples Prepared By Different Methods.

P. Karmwar, K. Graeser, K. Gordon, C. Strachan, T. Rades
Published 2011 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The aim of this study was to investigate if amorphous indomethacin samples, prepared using different preparation methods, exhibit different structural and kinetic characteristics and if these differences can be correlated to their physical stability (time to crystallisation). Samples were prepared by melt quenching, spray drying, ball milling, and cryo-milling. The resulting amorphous materials were characterised using X-ray diffraction, Raman spectroscopy and differential scanning calorimetry. All freshly prepared samples were completely X-ray amorphous (with a halo being the only feature in the diffractograms). The shape of the halos in the diffractograms, however, varied depending on the preparation method, suggesting structural variations in the near order of the molecules between the differently prepared amorphous forms. Principal component analysis of the Raman spectra of the various amorphous forms revealed that the samples clustered in the scores plot according to preparation method, again suggesting structural differences due to preparation method. The range of vibrations associated with the largest spectral differences in the loadings plot showed that these differences were due to a range of molecular conformations and intermolecular interactions. The ranking of the samples with respect to stability was: quench cooled amorphous samples>cryo-milled (α-form)>spray dried>ball milled (α-form)>ball milled (γ-form)=cryo-milled (γ-form). This ranking was not correlated with the diffractogram shapes or sample distribution in the scores plot of the Raman spectra, suggesting that physical stability was not directly affected by structural variation in the samples. However, ranking of stability of the differently prepared amorphous forms of the drug could be predicted by determining the relaxation time values, for all amorphous samples. The relaxation times, calculated by using the Adam Gibbs and Kohlrausch-Williams-Watts equations, were in accordance with the experimentally determined stability order. This study showed that correlation of physical stability with calculated relaxation time is possible for the same amorphous systems prepared by different methods. This could aid in selecting the most appropriate preparation techniques in situations where there are a variety of suitable methods.
This paper references
A theoretical and spectroscopic study of gamma-crystalline and amorphous indometacin.
C. Strachan (2007)
10.1248/CPB.33.3447
Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol.
N. Kaneniwa (1985)
10.1211/jpp.59.2.0012
A theoretical and spectroscopic study of γ‐crystalline and amorphous indometacin
C. Strachan (2007)
10.1023/A:1011082309058
Usefulness of the Kohlrausch-Williams-Watts Stretched Exponential Function to Describe Protein Aggregation in Lyophilized Formulations and the Temperature Dependence Near the Glass Transition Temperature
S. Yoshioka (2004)
10.1002/JPS.21162
Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times.
C. Bhugra (2008)
10.1002/JPS.2600581004
Determination of the degree of crystallinity in solid-solid equilibria.
D. J. Alen (1969)
10.1107/S160053680301506X
Indomethacin tert-butanol solvate at 120 K
P. Cox (2003)
10.1016/J.TCA.2005.02.014
Measurement of enthalpic relaxation by differential scanning calorimetry—effect of experimental conditions
R. Surana (2005)
10.1248/CPB.16.17
1-acyl-indoles. II. A new syntheses of 1-(p-chlorobenzoyl)-5-methyoxy-3-indolyacetic acid and its polymorphism.
H. Yamamoto (1968)
10.1016/J.EJPS.2007.07.003
Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy.
A. Heinz (2007)
10.1136/bmj.3.5720.449
Non-steroid anti-inflammatory agents.
H. Mizushima (1970)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1002/JPS.10181
Dynamics of pharmaceutical amorphous solids: the study of enthalpy relaxation by isothermal microcalorimetry.
J. Liu (2002)
10.2174/156720109789000492
Applying thermodynamic and kinetic parameters to predict the physical stability of two differently prepared amorphous forms of simvastatin.
K. Graeser (2009)
The polymorphism of indomethacine. New modifications, their melting behavior and solubility.
L. Borka (1974)
10.1002/CHIN.199713319
Characteristics and Significance of the Amorphous State in Pharmaceutical Systems
Bruno C. Hancock (1997)
10.1063/1.2820148
Physics of Amorphous Materials and The Physics of Amorphous Solids
S. R. Elliott (1987)
ANTI-INFLAMMATORY AND ANTIPYRETIC ACTIVITIES OF INDO-METHACIN, 1-(p-CHLOROBENZOYL)-5-METHOXY-2-METHYL-INDOLE-3-ACETIC ACID
C. Winter (1963)
10.1016/S0939-6411(99)00013-2
Stability prediction of amorphous benzodiazepines by calculation of the mean relaxation time constant using the Williams-Watts decay function.
G. Van den Mooter (1999)
10.1248/CPB.28.2565
Stability and several physical properties of amorphous and crystalline form of indomethacin.
H. Imaizumi (1980)
10.1063/1.1696442
On the Temperature Dependence of Cooperative Relaxation Properties in Glass‐Forming Liquids
G. Adam (1965)
10.1016/S0169-409X(01)00098-9
Amorphous pharmaceutical solids: preparation, characterization and stabilization.
L. Yu (2001)
10.1021/JA00887A038
Non-Steroid Anti-Inflammatory Agents
T. Shen (1963)
10.1007/s11095-006-9071-9
A Calorimetric Method to Estimate Molecular Mobility of Amorphous Solids at Relatively Low Temperatures
C. Mao (2006)
10.1021/JS9501091
Effects of solid-state processing on water vapor sorption by aspirin.
Bruno C. Hancock (1996)
10.1021/CG700913M
Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin
K. Graeser (2008)
10.1023/A:1012167410376
Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions
L. Taylor (2004)
Anti - inflammatory and antipyretic activities of indomethacin , 1 - ( p - chlorobenzoyl ) - 5 - methoxy - 2 - methyl - indole - 3 - acetic acid
H. Yamamoto (1968)
10.1002/JPS.21219
Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin.
T. Feng (2008)
10.1016/J.EJPS.2006.10.010
Screening for differences in the amorphous state of indomethacin using multivariate visualization.
M. Savolainen (2007)
10.1016/S0378-5173(98)00338-X
The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems.
D. Craig (1999)
10.1016/j.bpc.2009.07.005
Evidence of alpha fluctuations in myoglobin's denaturation in the high temperature region: Average relaxation time from an Adam-Gibbs perspective.
L. Olivares-Quiroz (2009)



This paper is referenced by
10.1002/9783527652693.CH15
Processing-Induced Disorder in Pharmaceutical Materials
S. Qi (2016)
Raman chemical and physical mapping of oral dosage forms
Francesco Tres (2015)
10.1016/j.ejpb.2014.12.018
Specific surface, crystallinity, and dissolution of lyophilized fibrinogen. A study by combined small- and wide-angle X-ray scattering (SWAXS).
V. Wahl (2015)
10.1021/acs.jpcb.7b05667
Molecular Mobility of an Amorphous Chiral Pharmaceutical Compound: Impact of Chirality and Chemical Purity.
Quentin Viel (2017)
From Molecule to Dose Form – Accelerated Bioavailability Enhancement for Early Phase Molecules
Jean-Luc Veuthey (2015)
10.1016/j.ejps.2016.08.022
Development of a screening method for co-amorphous formulations of drugs and amino acids.
G. Kasten (2016)
10.1021/mp400498n
Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy.
Xiaoda Yuan (2014)
10.1021/acs.molpharmaceut.7b00382
A New Method To Identify Physically Stable Concentration of Amorphous Solid Dispersions (I): Case of Flutamide + Kollidon VA64.
K. Chmiel (2017)
10.1140/EPJST/E2016-60233-Y
Study of the molecular mobility of (±)-methocarbamol in the amorphous solid state
J. J. Moura Ramos (2017)
10.1002/jps.24027
Sucrose/Glucose molecular alloys by cryomilling.
A. Megarry (2014)
10.1016/j.ijpharm.2012.04.066
Emerging trends in the stabilization of amorphous drugs.
R. Laitinen (2013)
10.2478/acph-2013-0026
Methods of amorphization and investigation of the amorphous state
Tomaž Einfalt (2013)
10.1016/j.xphs.2015.12.012
Three-Dimensional Printed PCL-Based Implantable Prototypes of Medical Devices for Controlled Drug Delivery.
J. Holländer (2016)
10.1039/C6RA18022A
Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride
Shuai Qian (2016)
10.1016/j.ejpb.2016.10.002
Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
Andreas Beyer (2016)
An Investigation into the Solid State Properties of Olanzapine and Paroxetine HCl and their Solid Dispersion Systems
M. F. Pina (2014)
10.1111/jphp.12494
Investigation of physical properties and stability of indomethacin–cimetidine and naproxen–cimetidine co‐amorphous systems prepared by quench cooling, coprecipitation and ball milling
Ai Wei Lim (2016)
Preparation and Characterisation of Pharmaceutical Solids – A
S. Patel (2017)
10.1021/mp3000698
Molecular dynamics simulation of amorphous indomethacin.
Tian-xiang Xiang (2013)
10.1016/j.xphs.2016.08.019
The Slow Relaxation Dynamics in the Amorphous Pharmaceutical Drugs Cimetidine, Nizatidine, and Famotidine.
M. T. Viciosa (2016)
10.1016/j.addr.2016.01.003
Recent developments in micro- and nanofabrication techniques for the preparation of amorphous pharmaceutical dosage forms.
S. Qi (2016)
10.1016/j.ejps.2011.08.010
Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
P. Karmwar (2011)
10.1016/j.xphs.2016.03.014
Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble Drugs.
K. Nurzyńska (2016)
10.1016/j.ijpharm.2017.04.011
Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium.
Andreas Beyer (2017)
10.1002/9781119600800.CH62
SPRAY DRYING AND AMORPHOUS DISPERSIONS
Kristin J. M. Ploeger (2019)
10.3390/pharmaceutics10030098
Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery
A. Karagianni (2018)
10.1016/j.ejpb.2016.04.019
Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
Andreas Beyer (2016)
10.1208/s12249-020-01802-0
Characterizing and Exploring the Differences in Dissolution and Stability Between Crystalline Solid Dispersion and Amorphous Solid Dispersion.
X. Wang (2020)
New binary solid dispersion of indomethacin and croscarmellose sodium: physical characterization and in vitro dissolution enhancement.
S. G. Castro (2012)
10.1016/j.ejpb.2014.07.013
The effect of processing on the surface physical stability of amorphous solid dispersions.
Z. Yang (2014)
10.1039/c7cp06664c
The significance of the amorphous potential energy landscape for dictating glassy dynamics and driving solid-state crystallisation.
M. Ruggiero (2017)
10.1021/acs.molpharmaceut.5b00688
Theoretical Considerations of the Prigogine-Defay Ratio with Regard to the Glass-Forming Ability of Drugs from Undercooled Melts.
Nicole Wyttenbach (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar